Aceragen Inc - Company Profile
Powered by 
All the sales intelligence you need on Aceragen Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Aceragen Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Aceragen Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Aceragen Catalyst Calendar
Proactively evaluate Aceragen Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.
A sample of Aceragen Catalyst Calendar data
| Event Date | Event Type | Company Name | Ticker Symbol | Drug Name | Therapy Area | Indication | Source Type |
|---|---|---|---|---|---|---|---|
| 01 May 2020 | GDCTWXYZ | Lorem | Lorem | Lorem | WXYZ | Planned | Lorem |
| 14 Dec 2019 | Phase I Trial Initiation | AbbVie Inc; Aceragen Inc | ABBV; IDRA | ABBV-368; budigalimab; tilsotolimod sodium | Oncology | Head And Neck Cancer Squamous Cell Carcinoma; Hypopharyngeal Cancer; Laryngeal Cancer; Oral Cavity (Mouth) Cancer; Oropharyngeal Cancer; Recurrent Head And Neck Cancer Squamous Cell Carcinoma; Solid Tumor | Clinical Trial Registry |
| 01 Dec 2019 | Phase I Trial Results | Aceragen Inc | IDRA | tilsotolimod sodium | Oncology | Breast Cancer; Chondrosarcoma; Colorectal Cancer; Esophageal Cancer; Gastrointestinal Stromal Tumor (GIST); Melanoma; Metastatic Breast Cancer; Metastatic Melanoma; Non-Small Cell Lung Cancer; Ocular Melanoma; Osteosarcoma; Ovarian Cancer; Pancreatic Cancer; Soft Tissue Sarcoma; Solid Tumor; Transitional Cell Carcinoma (Urothelial Cell Carcinoma); Unspecified Cancer | Conferences |
| 01 Dec 2019 | Phase I/II Trial Results | Aceragen Inc; University of Texas MD Anderson Cancer Center | IDRA | tilsotolimod sodium | Oncology | Melanoma; Metastatic Melanoma | Company Presentation |
Feature
Catalyst Calendar provides forecasted drug development milestones within the Pharma industry including expected timing, expected outcomes and possible financial impacts.
Benefit
Access:
- Trial Events for trials conducted globally by a company, university, institute or CRO: Trial Initiation, Trial Completion, Trial Results
- Regulatory Events related to drug filings with regulatory bodies, approvals and commercial launches. This is covered for the US, EU and Japan
- Intellectual Property Events for patent and exclusivity expiry specific to the US, EU and Japan: Constraining Patent Expiry (US/EU/Japan), Drug Expiry (US/EU/Japan), Commercial Launch (US/EU/Japan)
Value
Proactively evaluate companies and catalyst impacts
Stay ahead of the competition & improve corporate planning
Bolster business development with timely opportunities
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer